CA IL10
Alternative Names: CA-IL10Latest Information Update: 28 Jun 2023
At a glance
- Originator University of California, San Diego
- Developer Cytonus Therapeutics; University of California, San Diego
- Class Anti-inflammatories; RNA
- Mechanism of Action Interleukin 10 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Transplant rejection
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 28 Jun 2023 No recent reports of development identified for preclinical development in Transplant-rejection(Prevention) in USA (Parenteral)
- 31 May 2019 Preclinical trials in Transplant rejection (Prevention) in USA (Cytonus Therapeutics pipeline, May 2019)